Oncolytic Virus Immunotherapy: Showcasing Impressive Progress in Special Issue II
Open Access
- 10 June 2021
- journal article
- editorial
- Published by MDPI AG in Biomedicines
- Vol. 9 (6), 663
- https://doi.org/10.3390/biomedicines9060663
Abstract
Cancer immunotherapy has recently become the most promising strategy for hard-to-treat, advanced-stage malignanciesThis publication has 25 references indexed in Scilit:
- Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapyMolecular Cancer, 2020
- Combination Immunotherapy Using Oncolytic Virus for the Treatment of Advanced Solid TumorsInternational Journal of Molecular Sciences, 2020
- Clinical landscape of oncolytic virus research in 2020Journal for ImmunoTherapy of Cancer, 2020
- A guide to cancer immunotherapy: from T cell basic science to clinical practiceNature Reviews Immunology, 2020
- Cold Tumors: A Therapeutic Challenge for ImmunotherapyFrontiers in Immunology, 2019
- The 2018 Nobel Prize in medicine goes to cancer immunotherapyBMC Cancer, 2018
- Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable MelanomaJournal of Clinical Oncology, 2018
- Oncolytic Virus Combination Therapy: Killing One Bird with Two StonesMolecular Therapy, 2018
- Lighting a Fire in the Tumor Microenvironment Using Oncolytic ImmunotherapyEBioMedicine, 2018
- Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 ImmunotherapyCell, 2017